Brief: Replicel life science says U.S. patent issued to co
April 25 (Reuters) - Replicel Life Sciences Inc RP.V
* Replicel Life Sciences Inc - United States patent issued
to Replicel for its novel dermal injection technologies
Source text for Eikon: urn:newsml:reuters.com:*:nCNWYcpVPa
Further company coverage: RP.V
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Replicel Life Sciences
See all newsBrief: Replicel Life Sciences Announces Reinstatement Of Trading & Conditional Acceptance For Proposed Transaction
Brief: Replicel Life Sciences Says Replicel Announces A Letter Of Intent For Asset Purchase Agreement
Brief: Replicel Announces Binding Term Sheet For Strategic Investment And U.S. Partnership
Brief: Replicel Announces Its Incoming Board Of Directors
Brief: RepliCel Life Sciences Retains Dermatology Sales And Marketing Executive To Guide Global Commercial Strategy For Automated Dermal Injector